SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals has entered into a definitive agreement to be…

CATALYST PHARMACEUTICALS, INC. · DEFA14A filed May 7, 2026 at 09:00 ET

At the news

BULLISHIMPACT 8/10

DEFA14A filed May 7, 2026 at 09:00 ET

Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and provides a 28% premium to the 30-day VWAP. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero, pushing generic entry to no earlier than January 2035.

  • Acquisition price of $31.50 per share in cash, total equity value ~$4.1 billion
  • 28% premium to 30-day VWAP as of April 22, 2026; 21% premium to unaffected closing price
  • Closing expected in Q3 2026, subject to stockholder approval, HSR, and other conditions
  • All directors and executive officers entered into voting agreements to support the merger

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access